A Multi-National, Prospective, Observational Study in Patients With Unresectable or Metastatic Melanoma
Active, no longer recruiting
Phase of Trial: Phase IV
Latest Information Update: 28 Jun 2018
At a glance
- Drugs Ipilimumab (Primary)
- Indications Malignant melanoma
- Focus Adverse reactions
- Acronyms IMAGE
- Sponsors Bristol-Myers Squibb
- 10 Apr 2018 Planned End Date changed from 30 Mar 2020 to 28 Nov 2020.
- 10 Apr 2018 Planned primary completion date changed from 29 Mar 2018 to 11 May 2020.
- 10 Apr 2018 Status changed from recruiting to active, no longer recruiting.